{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgN69u88KDA","lastupdate":"2022-09-05T00:00:00.000Z","update_date":"2022-09-05T00:00:00.000Z","lastModified":"Sep 2, 2025","active":1,"confidence_score":93,"confidence_score_reason":"markets, not claimed","urlname":"amorphical","minimal_profile":null,"status":"","fullstatus":"","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$symQulHTHPybonMVBu3tn5hPoysckCaoNg17fKqbuYYt1wnLVrheaG","name":"Amorphical","oneliner":"Amorphous Calcium Carbonate Products","registrar":"513562686","website":"https://www.amorphical.com","careerspage":"","founded_month":7,"founded_year":2004,"formernames":[],"sociallinks":{"twitter":"","youtube":"https://www.youtube.com/channel/UCPSTPSBS2Kvojy6kliNYwzw","facebook":"https://www.facebook.com/amorphicure","linkedin":"https://www.linkedin.com/company/72009079","instagram":""},"social":["https://www.youtube.com/channel/UCPSTPSBS2Kvojy6kliNYwzw","https://www.facebook.com/amorphicure","https://www.linkedin.com/company/72009079","https://www.amorphical.com","https://amorphicure.co.il"],"flattenedsociallinks":"https://www.youtube.com/channel/UCPSTPSBS2Kvojy6kliNYwzw|https://www.facebook.com/amorphicure|https://www.linkedin.com/company/72009079|https://www.amorphical.com|https://amorphicure.co.il","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":1,"employees":"11-50","employees_exact":22,"patent":1,"raised":28300000,"stage":"F","public_stage":"F","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":["Density"],"about":"Amorphical is a pioneering biotechnology company that develops and manufactures unique natural-based medicines and dietary supplements with high bio-availability, aiming at the improvement of calcium absorption and management, in tandem with balancing the body's acidity level (pH) derived by various biomedical conditions. These features are critical for maintaining health, repairing bone deficiencies, treating severe diseases, and aiding the development and strengthening of the body.\n\nAmorphical’s leading scientists succeeded in stabilizing and preserving a rare natural form of calcium used by blue crayfish to develop a unique nanometric substance called amorphous calcium carbonate, which helps improve people's health and quality of life.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"+97286995333","country":null,"address":{"israeli":[{"id":"876fe123-71ce-47bb-842b-89f2b2d6220c","city":"Ness Ziona","type":null,"address":"HaHarash Street 11, Nes Ziyyona, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":null},"headquarter_address":null,"district":"Center District","news":[{"id":"pCv8cjK3mXxmoXWr1XqkX3iGdBIUwTgDLRljiUgSuvcVxHrCd7bVno","date":"Sep 30, 2025","link":"https://www.prnewswire.com/il/news-releases/amorphical-announces-positive-interim-results-from-ongoing-clinical-trial-in-crohns-disease-302570515.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"clinical trial","round":null,"company":"Amorphical","layoffs":null,"summary":"Amorphical, a biotechnology company, announced positive interim results from its ongoing open-label clinical trial for a nano-amorphous mineral-based therapy targeting moderate-to-severe Crohns disease. The investigational therapy, which aims to normalize the acidic microenvironment in the gut, showed significant clinical improvement and remission in patients. The trial, conducted in Israel, has enrolled 22 patients, with 17 providing open-label data. The results will inform Amorphicals future FDA regulatory strategy. The company is also advancing clinical programs in other conditions, supported by a robust patent portfolio and GMP-certified manufacturing infrastructure.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["Crohns disease","clinical trial","nano-amorphous","therapy","FDA strategy"],"date_of_event":"November 2023","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","FDA approved/pending approval"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage  #FDA approved/pending approval","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"z0qSHIhM4Dz6qdIDizzrz6ibsWy4YV4iNaxiIiikeytJSVDME1IArd","news_summary":"/PRNewswire/ -- Amorphical, developer of nano-amorphous mineral-based pharmacologic agents for health conditions, today announced positive interim results from...","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"cRQZQwcB2gZwLOSJBL8JrOADINm82Gt4wc7mcpAlsZmI7vIlwXAsvu","date":"Sep 2, 2025","link":"https://www.prnewswire.com/il/news-releases/amorphical-appoints-eden-ben-as-ceo-as-company-advances-regulatory-pathway-for-nano-amorphous-mineral-based-therapeutics-302543555.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"management changes","round":null,"company":"Amorphical","layoffs":null,"summary":"Amorphical, a biotechnology company specializing in nano-amorphous mineral-based pharmacologic agents, has appointed Eden Ben as its new CEO. The company is advancing its pipeline of disease-modifying therapies targeting conditions such as hypoparathyroidism, pancreatic cancer, osteoporotic fractures, and Crohns disease. With a focus on regulatory pathways in the U.S. and Europe, Amorphical is leveraging its proprietary technology to enhance bioavailability and optimize pH balance at the cellular level. The company is currently conducting a Phase 2 trial for hypoparathyroidism under FDA oversight and plans further studies for other conditions. The appointment of Ben is seen as a strategic move to accelerate the companys development and regulatory milestones.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["nano-amorphous","clinical trials","regulatory strategy","disease-modifying","bioavailability"],"date_of_event":null,"product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Management Changes","Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Management Changes  #Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Bt4mnGIJpzJWoLyD00ek7ng8Ro81EqeKAmbjpY3rRD60cNqeisYkUg","news_summary":"/PRNewswire/ -- Amorphical, developer of nano-amorphous mineral-based pharmacologic agents for health conditions, announced today the appointment of Eden Ben...","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"N0jAZXMrvpnszzTlWyvKQzX91uOhjKYjzpkVNiFimIIajwSvksfFn6","date":"Jun 13, 2022","link":"https://www.israelhayom.com/2022/06/13/israeli-shellfish-based-calcium-breakthrough-tested-in-space/","source":"www.israelhayom.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"IkWttD9IyiKb5B2uuAUeUOKEj5YUw8yx9ZLQPoTF3iHMMqgbguX9HF","news_summary":"https://www.israelhayom.com/2022/06/13/israeli-shellfish-based-calcium-breakthrough-tested-in-space/","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"Xqsugg3cY17mfEXhhSZcR5jQ93iasqNrTL3SESxvhO4fxTdSPMQCUh","date":"Jan 6, 2022","link":"https://newsdirect.com/news/outstanding-preliminary-results-of-a-clinical-trial-treating-moderate-to-severe-covid-19-patients-conducted-by-amorphical-an-israeli-biotechnology-company-973592489","source":"newsdirect.com","visible":1,"analysis":{"tags":["COVID-19 treatment"],"company":"Amorphical","layoffs":null,"summary":"Amorphical, an Israeli biotech company, has announced positive interim results from a Phase II clinical study of its COVID-19 treatment drug, AMOR-18. The study showed that patients hospitalized with moderate-to-severe COVID-19 who received AMOR-18 had a significantly reduced risk of ICU admission and mortality compared to those in the placebo group. None of the patients treated with AMOR-18 were transferred to the ICU or died, while 32% of the placebo group were transferred to the ICU and 10% died. The study is ongoing, and Amorphical plans to complete Phase II and proceed to Phase III. The company is also in the approval process to conduct a similar study in Brazil. AMOR-18 is based on Amorphicals unique amorphous calcium carbonate (ACC) technology.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["COVID-19","clinical study","ACC treatment","interim analysis","hospitalized patients"],"date_of_event":"January 06, 2022","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"o0UKXyxFGoNdn9rJSwsf4togWzd48j76QrmozqjhGRRHHHa0Sgn3hr","news_summary":"Outstanding Preliminary Results of A Clinical Trial Treating Moderate-To-Severe Covid-19 Patients, Conducted By Amorphical, An Israeli Biotechnology Company | News Direct","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"a9af7385-94bc-40fa-8f8e-23734fed3560","date":"Dec 9, 2020","link":"https://www.calcalist.co.il/internet/articles/0,7340,L-3880433,00.html?_atscid=7_134353_204082920_1690157_0_Txtetaxjxdshwhus8sp","source":"www.calcalist.co.il","visible":1,"analysis":{"tags":"biotechnology, fundraising","company":"אמורפיקל","layoffs":null,"summary":"Israeli biotechnology company Amorphical has raised $30 million in a Series F funding round. The private placement includes existing and new investors, with UIC Group from Taiwan investing $1 million. In addition to the investment, UIC Group has signed an agreement to purchase Amorphicals products for $17.5 million and market them in Taiwan. The funds will be used for clinical trials of Amorphicals technology for treating secondary bone cancer. The company has also received a patent approval in the US for its amorphous calcium carbonate (ACC) technology, which is derived from blue algae and used in the treatment of blood cancer. Amorphical has raised a total of $23 million in previous funding rounds.","partners":"UIC Group","customers":null,"investors":"UIC Group","confidence":9,"key_topics":["biotechnology","fundraising","cancer treatment","calcium carbonate","private placement"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$30 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"h4wpL7JnWXx3lNCgBquA73CaRvusb3c88LqLHVFvfKkuUBPbtvCf6R","news_summary":"אמורפיקל שמפיקה סידן מסרטנים כחולים יוצאת לגיוס של 30 מיליון דולר לפי שווי של 160 מיליון דולר","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"74427fdb-9b9c-4bff-8555-35d827ba62d3","date":"Aug 3, 2017","link":"http://www.globes.co.il/en/article.aspx?did=1001199700&from=iglobes","source":"www.globes.co.il","visible":1,"analysis":{"tags":"medical research","company":"Amorphical","layoffs":null,"summary":"Amorphical, a company that produces amorphous calcium capsules, has signed a marketing and distribution agreement with China Meheco in China. The company estimates revenue of a few million dollars in 2017 and $20-40 million in 2018 from the deal. Amorphical plans to expand its staff and is currently in a financing round at a company value of $110 million. The company is also conducting medical research on the use of amorphous calcium for the treatment of cancer. Amorphical was founded by CEO Yossi Ben, who discovered the technology while raising blue crabs.","partners":["China Meheco"],"customers":null,"investors":"Yossi Ben","confidence":9,"key_topics":["Amorphical","marketing agreement","China","revenue","investor"],"date_of_event":"August 3, 2017","valuation_amount":"$110 million","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Expand"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"vAc8khEK8TxsaXYRwApYGixjfEIYJtEyLmXKydl44gmzllDKw1CSkp","news_summary":"Amorphical signs China calcium capsule deal","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"811e6a88-5567-4813-a933-e15a4cb02e27","date":"Mar 17, 2014","link":"http://www.globes.co.il/en/article-amorphical-calcium-absorption-trial-successful-1000925022","source":"www.globes.co.il","visible":1,"analysis":{"tags":"clinical trial","company":"Amorphical Ltd.","layoffs":null,"summary":"Amorphical Ltd. has successfully completed a clinical trial of its new kind of calcium, amorphous calcium, which is absorbed better by the body than crystalline calcium. The trial found that patients absorption of amorphous calcium was double that of crystalline calcium. The company aims to develop a product as a nutritional supplement and medication. Amorphical has raised $1.2 million from private investors.","partners":null,"customers":null,"investors":"private investors","confidence":8,"key_topics":["amorphous calcium","clinical trial","nutritional supplement","osteoporosis","blue crayfish"],"date_of_event":"March 17, 2014","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$1.2 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"SotHNJoemSTCWuLRWfnADBWdFH6k6DMGVUpYy81nwpThYQgDugwYqi","news_summary":"Amorphical calcium absorption trial successful","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":7,"techcommunityinvolvement":null,"mediagallery":[{"id":"9ba33fe9-fd0c-489d-961e-b89c4679d9a9","timestamp":"2022-05-16 09:21:00.000000","resources_type":2,"resources_title":"","resources_file_name":"KNPFp3efQBs","alt":"","imageurl":"https://img.youtube.com/vi/KNPFp3efQBs/0.jpg","url":"http://youtu.be/KNPFp3efQBs"},{"id":"81fb8ead-6445-47c9-ae02-362ac608bbe7","timestamp":"2020-12-15 11:33:40.000000","resources_type":1,"resources_title":"Density1","resources_file_name":"$FWvME5Q5qtiaTeOc7iqN7JORqwH4XJ6Xg6ddPthBRMsy0kDtxXCm8v","alt":"Density1 logo","cleanBucketUrl":"https://storage.googleapis.com/clean-finder-353810","imageurl":"https://storage.googleapis.com/clean-finder-353810/$FWvME5Q5qtiaTeOc7iqN7JORqwH4XJ6Xg6ddPthBRMsy0kDtxXCm8v","url":"https://storage.googleapis.com/clean-finder-353810/$FWvME5Q5qtiaTeOc7iqN7JORqwH4XJ6Xg6ddPthBRMsy0kDtxXCm8v"},{"id":"560ad158-3204-4a04-8ed4-6dfd5418214c","timestamp":"2015-05-05 07:56:58.000000","resources_type":2,"resources_title":"","resources_file_name":"IjkHTkLB_Qs","alt":"","imageurl":"https://img.youtube.com/vi/IjkHTkLB_Qs/0.jpg","url":"http://youtu.be/IjkHTkLB_Qs"}],"tags":["pharmaceuticals","supplements","biotechnology","nutrition","investors","private-investors","pharma-companies","novel-ingredients","hospitals","wellness","osteoporosis","cancer","space-tech"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PvppskJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PvavvYLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puom_sKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA"],"technologysuccessstory":[{"date":"2004-07-01","name":"Development and manufacture of a proprietary synthetic form of calcium","tags":["molecular-biology","biotechnology"],"category":"Life Sciences & Biotechnology","tto_logo":"/image_cloud/bgn-technologies1_tto_logo_d432a8a3-6016-11e8-8ef8-41fdcbb0dda6","university_logo":"/image_cloud/bgn-technologies1_institution_logo_d432a8a3-6016-11e8-8ef8-41fdcbb0dda6"}],"usecases":[],"businessmodels":["B2B","B2B2C"],"productstage":"Released","products":["DENSITY","AMOR-18","pHGastrilex","pHdirect","pHkids","pHsport"],"geomarkets":["Taiwan","Israel","Hong Kong","China"],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":2,"lastfunding":"$6M","totalrounds":6,"fundingstage":"F","totalfunding":"$28.3M","publicinvestors":2,"lastpublicfunding":6000000,"totalpublicrounds":6,"totalpublicfunding":28300000},"team":[{"name":"Yossi Ben","email":"yossi@amorphical.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgLG1i5wJDA","bounced":false,"claimed":0,"founder":1,"urlname":"yossi-ben","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICA8fS1ywoM","position":"Founder & Chairman","last_name":"Ben","claimtoken":"mZm4NNSOoNmhpyS40XxOFx317Iwv6IHt51DpSCSY2VI9fP78BhHbab","first_name":"Yossi","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/yossi-ben-866280207/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2022-09-05 18:28:05.000000","initials":"YB","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Eden  Ben","email":"eden@amorphical.com","phone":"","gender":"Male","userid":"c2KHlXGaDgcWZI8bXJOOqeOaIczIfmxVLoRD6aN4xGbnwM5BXR66hr","bounced":false,"claimed":1,"founder":0,"urlname":"eden-ben","visible":1,"memberid":"ZH3xQ23Qixk7X9Blfl5Gdso3yt5svbb2DeWCga6fOajvzX628BQ11d","position":"CEO","last_name":"Ben","claimtoken":"FfB7r0CLfhViLKgd2Fc0V9Y9IMBhRR0SkAlREOqh2vzx1lUG6LL5yP","first_name":"Eden ","picturekey":null,"claimeddate":"2023-09-26","linkedinurl":"https://www.linkedin.com/in/eden-ben-a189a31b6/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2023-09-22 13:45:31.000000","initials":"EB","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Yigal Blum","email":"yigal@amorphical.com","phone":"","gender":"Male","userid":"f1ogLTYSnLKgpUiHF2pfp3SCCSy93ng9juTGyEYnb9nJzsKRjRIWzW","bounced":false,"claimed":null,"founder":0,"urlname":"yigal-blum","visible":1,"memberid":"VTSAJkK0VIXjJbcU2Igkrlfd3UBBrjDnezRFjj69WNSIc913nGNteB","position":"CTO","last_name":"Blum","claimtoken":"Kow7oyL62SOAh7fmEchXrlyL76IdXA88AujhEM72YfFovAhaZZ3Nfx","first_name":"Yigal","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/yigal-blum-5478874/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2022-09-05 18:29:18.000000","initials":"YB","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Pharmaceuticals","sectorverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgPGylJ0IDA","fullname":"Natalia Golczar"},"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgMGgoMMJDA","fullname":"Yanina Wainscheinker"},"biverifydate":"2020-02-24T00:00:00.000Z","crunchbaseid":"amorphical","lastupdator":"Yanina Wainscheinker","lastupdator_email":"yanina.wainscheinker@sncentral.org","creator":null,"creator_email":null,"createdate":"2014-11-24T00:00:00.000Z","biverification":"Yanina Wainscheinker","sectorverification":"Natalia Golczar","affiliatedOrganizations":null,"timeline":[{"id":"f6jnkBJIWV3WQlgrJkeEizR8A6rBqyJBFJlwcYDuIeI5HheLyNodCO","date":"Jan 2021","amount":"$6M","source":"","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"F Round","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":6000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"Z6i7eyG1OWyRxg93Z11qWxPUXrjmnPAwZzFE5DYzt5G0jWiUPX8Xtb","date":"Jan 2020","amount":"$1M","source":"","eventtype":"FundingRoundEvent","investment":[{"name":"ICU group","type":"Company","amount":null,"hidden":true,"country":"Asia","fullurl":"/company_page/icu-group","logokey":null,"tagline":"A company that sells supplements in Taiwan","urlname":"/company_page/icu-group","isisraeli":null,"investorid":"jRCu2b8xTak4p5KxOKNPOjifw8be38dMasqQflrqxWkxxMh88Mvi4I","fundingtype":"Company","leadpartner":null,"investmentid":"0htnAROlmiiltmKtvksh7w5VSNaOoCW3Uvb4Lio6gVveA3G9qMrfij","fundingsubtype":null,"investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/startups-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"F Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":1000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJCgr_TVCgw","date":"May 2016","amount":"$8.8M","source":"https://www.calcalist.co.il/technology/article/h11ubb5nt?_atscid=7_134353_204082920_1967752_0_Txtetaxjxdshwhus8sp","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"E Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":8800000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCEv6DHCww","date":"Mar 2014","amount":"$8M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"C Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":8000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"LURhuTnhBdtX3ZHYyvoDlTIrfo3QlCLg9fGfLtZlitoS7aLBup1zCH","date":"May 2013","amount":"$2.7M","source":"","eventtype":"GrantEvent","granttype":1,"investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":2700000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCkmqmqCgw","date":"Mar 2010","amount":"$1.8M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Undisclosed Investor(s)","type":"Investor","amount":0,"hidden":false,"country":"Europe","fullurl":"/investor_page/undisclosed-investor-s","logokey":null,"tagline":"","urlname":"/investor_page/undisclosed-investor-s","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCE3L3CCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"1024bce1-696e-4e8f-a42f-930621c1552a","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":1800000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"7/2004","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"Amorphical","logourl":"https://storage.googleapis.com/clean-finder-353810/$symQulHTHPybonMVBu3tn5hPoysckCaoNg17fKqbuYYt1wnLVrheaG","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$symQulHTHPybonMVBu3tn5hPoysckCaoNg17fKqbuYYt1wnLVrheaG","seoabout":"Amorphical is a pioneering biotechnology company that develops and manufactures unique natural-based medicines and dietary supplements with high bio-availa...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":3,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Materials & Substances","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Industrial Manufacturing","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puom_sKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Discrete Industries","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PvppskJDA","classificationName":"targetcustomer"},{"depth":3,"name":"Aerospace","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PvavvYLDA","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"},{"depth":3,"name":"Biotechnology","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Patients","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","classificationName":"targetcustomer"}],"classificationDelimited":["IndustryClassificationModel>Industrial Manufacturing#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puom_sKDA>Discrete Industries#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PvppskJDA","IndustryClassificationModel>Industrial Manufacturing#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puom_sKDA>Discrete Industries#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PvppskJDA>Aerospace#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PvavvYLDA","IndustryClassificationModel>Industrial Manufacturing#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puom_sKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA>Patients#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","TechnologyClassificationModel>Materials & Substances#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA"],"classificationsViewModel":"|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Industrial Manufacturing#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puom_sKDA|2:>IndustryClassificationModel>Industrial Manufacturing#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puom_sKDA/Discrete Industries#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PvppskJDA|3:>IndustryClassificationModel>Industrial Manufacturing#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puom_sKDA>Discrete Industries#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PvppskJDA/Aerospace#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PvavvYLDA|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA/Patients#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Materials & Substances#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Drugs Discovery & Development","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drugs Discovery & Development"}]}]}],"targetCustomer":[{"title":"Industrial Manufacturing","key":"0-0","path":"IndustryClassificationModel>Industrial Manufacturing","children":[{"title":"Discrete Industries","key":"0-0-0","path":"IndustryClassificationModel>Industrial Manufacturing>Discrete Industries","children":[{"title":"Aerospace","key":"0-0-0-0","path":"IndustryClassificationModel>Industrial Manufacturing>Discrete Industries>Aerospace"}]}]},{"title":"Healthcare & Life Sciences","key":"0-1","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Life Sciences","key":"0-1-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Pharmaceuticals","key":"0-1-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Pharmaceuticals"},{"title":"Biotechnology","key":"0-1-0-1","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Biotechnology"}]},{"title":"Healthcare","key":"0-1-1","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare","children":[{"title":"Patients","key":"0-1-1-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare>Patients"}]}]}],"coreTechnology":[{"title":"Materials & Substances","key":"0-0","path":"TechnologyClassificationModel>Materials & Substances"}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Materials & Substances","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Industrial Manufacturing","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puom_sKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Discrete Industries","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PvppskJDA","classificationName":"targetcustomer"},{"depth":3,"name":"Aerospace","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PvavvYLDA","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"},{"depth":3,"name":"Biotechnology","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Patients","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology","Drugs Discovery & Development"],"coreTechnology":["Materials & Substances"],"targetCustomer":["Industrial Manufacturing","Discrete Industries","Aerospace","Healthcare & Life Sciences","Life Sciences","Pharmaceuticals","Biotechnology","Healthcare","Patients"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"inline","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[{"id":"f6jnkBJIWV3WQlgrJkeEizR8A6rBqyJBFJlwcYDuIeI5HheLyNodCO","date":"Jan 2021","amount":"$6M","source":"","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"F Round","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":6000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"Z6i7eyG1OWyRxg93Z11qWxPUXrjmnPAwZzFE5DYzt5G0jWiUPX8Xtb","date":"Jan 2020","amount":"$1M","source":"","eventtype":"FundingRoundEvent","investment":[{"name":"ICU group","type":"Company","amount":null,"hidden":true,"country":"Asia","fullurl":"/company_page/icu-group","logokey":null,"tagline":"A company that sells supplements in Taiwan","urlname":"/company_page/icu-group","isisraeli":null,"investorid":"jRCu2b8xTak4p5KxOKNPOjifw8be38dMasqQflrqxWkxxMh88Mvi4I","fundingtype":"Company","leadpartner":null,"investmentid":"0htnAROlmiiltmKtvksh7w5VSNaOoCW3Uvb4Lio6gVveA3G9qMrfij","fundingsubtype":null,"investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/startups-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"F Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":1000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJCgr_TVCgw","date":"May 2016","amount":"$8.8M","source":"https://www.calcalist.co.il/technology/article/h11ubb5nt?_atscid=7_134353_204082920_1967752_0_Txtetaxjxdshwhus8sp","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"E Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":8800000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCEv6DHCww","date":"Mar 2014","amount":"$8M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"C Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":8000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCkmqmqCgw","date":"Mar 2010","amount":"$1.8M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Undisclosed Investor(s)","type":"Investor","amount":0,"hidden":false,"country":"Europe","fullurl":"/investor_page/undisclosed-investor-s","logokey":null,"tagline":"","urlname":"/investor_page/undisclosed-investor-s","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCE3L3CCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"1024bce1-696e-4e8f-a42f-930621c1552a","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":1800000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[{"id":"LURhuTnhBdtX3ZHYyvoDlTIrfo3QlCLg9fGfLtZlitoS7aLBup1zCH","date":"May 2013","amount":"$2.7M","source":"","eventtype":"GrantEvent","granttype":1,"investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":2700000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"merger_acquisitions":[],"others":[]}}